Breaking News Instant updates and real-time market news.

CMCSA

Comcast

$36.66

-2.92 (-7.38%)

, FOXA

21st Century Fox

$37.63

-1.18 (-3.04%)

16:46
02/27/18
02/27
16:46
02/27/18
16:46

On The Fly: Top stock stories for Tuesday

Stocks opened little changed and seemingly unaffected by the early economic data - including the trade balance report, retail inventory data, and durable goods orders - that were all below expectations. The silver lining was a report on consumer confidence, which showed a much higher than expected result. The averages moved to session highs before Fed Chairman Powell began speaking before the House Finance Committee, though the averages drifted lower as he testified. The market closed with broad-based losses as the Fed chair's remarks raised questions about whether the central bank may add another rate hike to its 2018 plans. ECONOMIC EVENTS: In the U.S., the Conference Board's Consumer Confidence Index increased to 130.8 in February from 124.3 in January, marking a new 17-year high. Durable goods orders dropped 3.7% in January, which was weaker than the 2% decline expected. The deficit in goods trade widened to $74.4B in January, according to the advance report. Exports declined 2.2% to $133.9B, while imports dipped 0.5% to $208.3B. The FHFA home price index edged up 0.3% to 256.9 in December. Additionally, new Fed chair Jerome Powell gave his semiannual monetary policy report before the Committee on Financial Services of the House of Representatives. COMPANY NEWS: Comcast (CMCSA) announced a possible offer which it says is a "superior cash proposal" to acquire Sky (SKYAY). Comcast's proposal of GBP12.50 per share represents a 16% increase in value over the existing 21st Century Fox offer (FOXA) and implies an equity value of $31B for Sky, reported the media giant, whose Class A shares fell over 7% following the announcement. Disney (DIS) CEO Bob Iger, whose company is in the process of buying much of Fox's assets, declined to comment to reporters on Tuesday regarding Comcast's offer for Sky, Reuters reported. Fox later said it stand behind its existing bid for Sky and that "no firm offer has been made" by Comcast for Sky at this point... Shares of Macy's (M) rose 3.5% after the company reported better than expected earnings, including a surprise increase in same-store sales during the holiday quarter. MAJOR MOVERS: Among the notable gainers was Macy's much-smaller department store rival Dillard's (DDS), which jumped 17% after its own earnings report. Also higher after reporting earnings report and increasing its FY18 profit view was hospital operator Tenet Healthcare (THC), which gained 9%. Among the noteworthy losers was Akorn (AKRX), which dropped 38% after Fresenius (FSNUY) said it is conducting an investigation into alleged FDA data breaches, which may affect the merger agreement between the companies. Also lower following their earnings reports were Nutrisystem (NTRI), which fell 21.5%, and Fitbit (FIT), which dropped 12.5%. Additionally, shares of AmerisourceBergen (ABC) fell 3% after CNBC, citing sources, said that the company's talks with Walgreens (WBA) regarding a potential acquisition have ended without a deal being reached. INDEXES: The Dow fell 299.24, or 1.16%, to 25,410.03, the Nasdaq lost 91.11, or 1.23%, to 7,330.35, and the S&P 500 declined 35.32, or 1.27%, to 2,744.28.

CMCSA

Comcast

$36.66

-2.92 (-7.38%)

FOXA

21st Century Fox

$37.63

-1.18 (-3.04%)

DIS

Disney

$104.87

-4.94 (-4.50%)

M

Macy's

$28.40

0.95 (3.46%)

DDS

Dillard's

$82.91

11.98 (16.89%)

THC

Tenet

$20.77

1.7 (8.91%)

AKRX

Akorn

$18.65

-11.63 (-38.41%)

FSNUY

Fresenius SE

$20.67

0.53 (2.63%)

NTRI

Nutrisystem

$31.30

-8.6 (-21.55%)

FIT

Fitbit

$4.86

-0.68 (-12.27%)

ABC

AmerisourceBergen

$97.64

-2.94 (-2.92%)

WBA

Walgreens Boots Alliance

$69.14

-1.46 (-2.07%)

CMCSK

Comcast

$58.00

(0.00%)

SKYAY

Sky

$74.58

12.98 (21.07%)

FOX

21st Century Fox

$37.14

-1.26 (-3.28%)

  • 27

    Feb

  • 27

    Feb

  • 27

    Feb

  • 27

    Feb

  • 01

    Mar

  • 01

    Mar

  • 05

    Mar

  • 18

    Mar

  • 28

    Mar

CMCSA Comcast
$36.66

-2.92 (-7.38%)

01/25/18
RHCO
01/25/18
NO CHANGE
Target $50
RHCO
Buy
Comcast price target raised to $50 from $45 at SunTrust
SunTrust analyst Greg Miller raised his price target on Comcast to $50 and kept his Buy rating after "solid" Q4 earnings, citing a more aggressive cash repatriation and encouraging guidance. Miller notes that while cable results were slightly below estimates, NBCU saw more "top-line momentum" and Xfinity wireless continued to gain subscribers. The analyst says he is bullish on the company's ability to grow and "generate significant free cash".
02/27/18
RBCM
02/27/18
NO CHANGE
RBCM
RBC says 21st Century Fox may let Comcast go ahead without counter-bid for Sky
After Comcast (CMCSA) proposed a cash offer for Sky (SKYAY) at a 16% premium to 21st Century Fox's (FOX) existing takeover bid, RBC Capital analyst Steven Cahall said that while he does not "profess to know the minds of the Murdochs" on the matter, he is inclined to think that Fox may let Comcast go ahead with its bid as the deal will no longer be "financially opportunistic" as it would have been. Adding that he was surprised Disney's (DIS) original deal for Fox included the Sky stake, Cahall said he's also "inclined to say" that Disney management "can live without Sky" and that the story is "unchanged, and arguably cleaner," without Sky. The analyst, who contends that Disney and Fox are best off letting Comcast "swoop in on Sky," has a Top Pick rating on Disney and an Outperform rating on 21st Century Fox.
01/28/18
PIPR
01/28/18
NO CHANGE
PIPR
Growth of sports rights may be coming down, says Piper Jaffray
Piper Jaffray analyst Stan Meyers says he is starting to see some evidence that the growth of sports rights may be coming down toward a more reasonable rate. The analyst notes that only CBS (CBS), Fox (FOXA) and NBC (CMCSK; CMCSA) submitted bids for Thursday Night Football rights, with CBS and NBC submitting bids below their current rate of $450M per year, and Fox making a higher bid for the rights, in a likely effort to establish itself as a "live sports and news" network in the wake of selling a majority of assets to Disney (DIS). On the digital side, Facebook (FB) declined to make an offer for digital streaming rights to TNF, while Amazon (AMZN), which paid $50M this year, and Twitter (TWTR), which paid $10M last year did submit bids.
01/18/18
01/18/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Symantec (SYMC) downgraded to Underperform from Hold at Jefferies with analyst John DiFucci saying the company's current guidance is not achievable and the stock will rerate lower upon investor realization. 2. Juno Therapeutics (JUNO) downgraded to Neutral from Buy at Citi with analyst Robyn Karnauskas saying Juno could be worth $110 per share in a takeover. 3. Comcast (CMCSA) downgraded to Neutral from Buy at Nomura Instinet with analyst Jeffrey Kvaal saying the company faces "heightened challenges" with over-the-top services driving declines in linear video and broadband growth likely to slow. 4. First Solar (FSLR) downgraded to Neutral from Buy at Guggenheim with analyst Sophie Karp citing valuation and limited near-term catalysts. 5. Chevron (CVX) downgraded to Hold from Buy at HSBC. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
FOXA 21st Century Fox
$37.63

-1.18 (-3.04%)

02/27/18
CHLM
02/27/18
NO CHANGE
Target $50
CHLM
Buy
Nutrisystem price target lowered to $50 from $80 at Craig-Hallum
Craig-Hallum analyst Alex Fuhrman lowered his price target for Nutrisystem to $50 from $80, citing guidance below estimates as the company "uncharacteristically" overpaid for pre-bought ads on Fox News (FOXA) & CNN (TWX). The analyst reiterates a Buy rating on Nutrisystem's shares.
01/22/18
ATLE
01/22/18
UPGRADE
ATLE
Overweight
21st Century Fox upgraded to Overweight from Neutral at Atlantic Equities
DIS Disney
$104.87

-4.94 (-4.50%)

02/07/18
HDLY
02/07/18
NO CHANGE
Target $134
HDLY
Long-Term Buy
Disney price target raised to $134 from $128 at Hilliard Lyons
Hilliard Lyons analyst Jeffrey Thomison raised his price target on Disney (DIS) shares to $134 after the company's "encouraging" Q1 results, stating that he believes each operating segment has growth potential over the next few years and he views the pending deal for 21st Century Fox (FOXA) assets as a long-term positive. He maintains a Long-Term Buy rating on Disney.
02/08/18
BMOC
02/08/18
NO CHANGE
Target $95
BMOC
Underperform
Disney price target raised to $95 from $90 at BMO Capital
BMO Capital analyst Daniel Salmon raised his price target on Disney to $95, noting a Q1 earnings beat, strong performance in Parks segment, and the upcoming launch of ESPN+. The analyst keeps his Underperform rating however, warning that shares could retest the bottom of recent range as the positive initial "virtual multichannel video programming distributor" impact fades.
02/07/18
MSCO
02/07/18
NO CHANGE
Target $130
MSCO
Overweight
Disney risks stabilizing while OTT opportunity grows, says Morgan Stanley
Morgan Stanley analyst Benjamin Swinburne noted that ESPN sub losses were stable to slightly better than the prior quarter for a second quarter in a row, while the emergence of Virtual Multichannel Video Programming Distributors and the benefit of renewals set the network up for improved results even before the benefit of the direct-to-consumer app. While the impact of lost third-party licensing as a result of a pivot to over-the-top won't be clear for a while, Swinburne thinks leaning towards OTT is likely the right strategic move, he added. He maintains an Overweight rating on Disney with a $130 price target.
M Macy's
$28.40

0.95 (3.46%)

01/05/18
BMOC
01/05/18
NO CHANGE
Target $38
BMOC
Outperform
Macy's price target raised to $38 from $35 at BMO Capital
BMO Capital analyst Wayne Hood raised his price target on Macy's to $38 and kept his Outperform rating after the company's Nov-Dec comps completed the first positive SSS Q4 since 2014. Hood notes "encouraging" improvement in brick-and-mortar comps as well as double digit growth in digital platforms, forecasting further upside from " improving consumer spending setup from tax reform and falling unemployment that could be far reaching". The analyst raises his FY17 EPS forecast to $3.63 from $3.53 and FY18 forecast to $3.18 from $2.63, reflecting a lower effective tax rate of about 25%.
01/02/18
MSCO
01/02/18
NO CHANGE
MSCO
Kohl's, Macy's Q4 same-store sales estimates raised at Morgan Stanley
Morgan Stanley analyst Kimberly Greenberger said that overall retail traffic appeared solid following Christmas, adding that store checks and third party data points suggest better performance at Kohl's (KSS) and Macy's (M) than she originally anticipated. Greenberger raised her Q4 Kohl's comparable sales estimate to down 1% from down 3% and increased her comp sales estimate for Macy's to down 2% from down 2.5%. However, she maintains an Underweight rating on Kohl's shares and an Equal Weight rating on Macy's.
12/18/17
OTRG
12/18/17
UPGRADE
OTRG
Mixed
Macy's upgraded to Mixed from Negative at OTR Global
OTR Global upgraded Macy's to Mixed following checks that indicate sell-through is meeting or exceeding plan driven by strong ecommerce trends.
02/05/18
JEFF
02/05/18
NO CHANGE
Target $100
JEFF
Buy
Bon-Ton Stores bankruptcy benefits Kohl's, says Jefferies
Jefferies analyst Randal Konik notes that Bon-Ton Stores filed bankruptcy protection and provided the locations of the about 50 units slated for closure. The analyst now estimates near-term closures from Macy's (M), Sears (SHLD), Kmart, and Bon-Ton (BONT) should add about 18c to Kohl's (KSS) EPS and a 1.5% comp lift. Moreover, Konik believes the materialization of Bon-Ton's closures could be a "cherry on top" to accelerating fundamentals at Kohl's this year. He reiterates a Buy rating and $100 price target on Kohl's shares.
DDS Dillard's
$82.91

11.98 (16.89%)

08/10/17
JPMS
08/10/17
NO CHANGE
Target $36
JPMS
Underweight
Dillard's price target lowered to $36 from $49 at JPMorgan
JPMorgan analyst Matthew Boss lowered his price target on Dillard's to $36 from $49 and reiterated an Underweight rating on the stock after the company reported quarterly losses, which it attributed to "significant markdowns" to deal with its inventory.
02/27/18
JPMS
02/27/18
NO CHANGE
Target $70
JPMS
Underweight
JPMorgan keeps Dillard's at Underweight, raises price target to $70
JPMorgan analyst Matthew Boss said Dillard's Q4 earnings beat illustrates the high degree of operating leverage in its model and noted that its same-store sales growth of 3% doubled his estimate, which he had raised during the quarter. Following the report, Boss raised his price target on Dillard's to $70 from $58, though he keeps an Underweight rating on the shares.
THC Tenet
$20.77

1.7 (8.91%)

12/20/17
MSCO
12/20/17
DOWNGRADE
MSCO
Underweight
HCA Healthcare, Tenet downgraded to Underweight at Morgan Stanley
As previously reported, Morgan Stanley analyst Zack Sopcak downgraded HCA Healthcare (HCA) and Tenet (THC), both to Underweight from Equal Weight, contending that the recently announced deals made by Aetna (AET) for CVS Health (CVS) and UnitedHealthcare (UNH) for DaVita Medical Group highlight the ways payers are becoming increasingly vertically integrated and focusing on reducing medical costs. After analyzing CVS Health's overlap with hospitals and hospitals' exposure to CVS and UnitedHealth (UNH) clinics in states with above average Medicare Advantage share, Sopcak found HCA and Tenet to be most exposed, he tells investors. Noting that he sees the valuations of both as full, he raised his price target on HCA to $84 from $79 and increased his target on Tenet to $15 from $14.
01/03/18
GSCO
01/03/18
INITIATION
Target $15
GSCO
Neutral
Tenet initiated with a Neutral at Goldman Sachs
Goldman analyst Stephen Tanal initiated Tenet with a Neutral and $15 price target due to unattractive payor mix, difficult local positioning, and competitive threats.
12/20/17
LEER
12/20/17
NO CHANGE
Target $27
LEER
Outperform
Value may be unlocked through Tenet sale of Conifer, says Leerink
Leerink analyst Ana Gupte raised her price target for Tenet to $27 from $25 on increased confidence that value may be unlocked through the active sale of Conifer. The analyst believes Conifer sales proceeds could be used for further debt reduction or growth opportunities in the ambulatory segment. He reiterates an Outperform rating on the shares.
12/20/17
MSCO
12/20/17
DOWNGRADE
MSCO
Underweight
Tenet downgraded to Underweight from Equal Weight at Morgan Stanley
AKRX Akorn
$18.65

-11.63 (-38.41%)

10/16/17
WELS
10/16/17
NO CHANGE
WELS
Outperform
Court ruling looks 'clearly negative' for Allergan, says Wells Fargo
Wells Fargo analyst David Maris says a federal judge ruling today that Allergan's (AGN) Restasis patents are invalid "appears clearly negative" for the company. Due to the magnitude of the potential damages involved, however, an at-risk generic launch is unlikely, Maris tells investors in an intraday research note. As such, the analyst continues to believe the earliest that a generic version of Restasis may enter the market is sometime in 2019. Maris keeps an Outperform rating on Allergan. He adds that today's court ruling is incrementally positive for generic Restasis filers, if approved, including Teva (TEVA), Mylan ( MYL) and Akorn (AKRN).
02/22/18
DBAB
02/22/18
NO CHANGE
DBAB
Hold
Akorn may be worth $9-$17 if Fresenius deal breaks, says Deutsche Bank
A "simple analysis implies significant downside" in shares of Akorn (AKRX) if the Fresenius SE (FSNUY) takeover breaks, Deutsche Bank analyst Gregg Gilbert tells investors in a research note. The analyst notes that since a speech on February 2 by the acting director of the Bureau of Competition at the FTC Bruce Hoffman, where he suggested that in transactions where complex drugs need to be divested, the FTC will require the divestiture of on-market products rather than pipeline products, the deal spread on Akorn's stock price and the $34 per share cash offer price has averaged 7% and is currently close to 8%. Assuming EBITDA multiples of 9-13 times for a standalone Akorn, the stock has a theoretical value of $9-$15 based on the company's Q3 EBITDA annualized and an $11-$17 share price based on estimated 2018 EBITDA, Gilbert writes. He keeps a Hold rating on Akorn with a $34 price target. He believes that the widening spread suggests concerns about the deal.
02/26/18
RAJA
02/26/18
NO CHANGE
RAJA
Market Perform
Akorn takeover by Fresenius 'may be kaput,' says Raymond James
In a research note titled "Die Fusion ist Kaput? Data Integrity Issues Likely Torpedo Fresenius Buy of AKRX," Raymond James analyst Elliot Wilbur believes the data integrity issues at Akorn (AKRX) could not only impact the company's approved products, but also its pipeline. Fresenius (FSNUY) has consistently touted the pipeline as key to the acquisition, which is now likely to be compromised, Wilbur contends. He believes Akorn could be valued at $8 per share if data integrity issues exist and the company's existing portfolio or pipeline are compromised. Akorn's base generics business has seen a "dramatic deterioration" over the past three quarters, Wilbur points out. He keeps a Market Perform rating on the stock.
02/27/18
JEFF
02/27/18
NO CHANGE
Target $34
JEFF
Hold
Akorn takeover by Fresenius may be in doubt, says Jefferies
The alleged Akorn (AKRX) data breaches by Fresenius SE (FSNUY) may put the terms of the merger agreement in doubt, Jefferies analyst David Steinberg tells investors in a research note. The use of consultants seems to signal Fresenius is looking to reprice or possibly terminate the merger, the analyst contends. He notes, however, that merger experts have generally viewed the transaction as "ironclad." Steinberg keeps a Hold rating on Akorn with a $34 price target.
FSNUY Fresenius SE
$20.67

0.53 (2.63%)

11/17/17
UBSW
11/17/17
DOWNGRADE
UBSW
Sell
Fresenius SE downgraded to Sell from Neutral at UBS
UBS analyst Ian Douglas-Pennant downgraded Fresenius SE to Sell saying he expects pricing pressure to spread to injectables. The rate of injectable generic drug approvals in the U.S. has increased 40% over the past year years, and those to compete against Fresenius' Kabi more than tripled, the analyst contends. He cut his price target for the shares to EUR 57 from EUR 74.
NTRI Nutrisystem
$31.30

-8.6 (-21.55%)

02/27/18
BRRR
02/27/18
DOWNGRADE
BRRR
Market Perform
Nutrisystem downgraded to Market Perform from Outperform at Barrington
Barrington analyst Matthew Gall downgraded Nutrisystem to Market Perform following last night's Q4 results. The company's flattish guidance for 2018, compared to double-digit growth expectations on sales and earnings, will likely put a ceiling on the stock for the next couple of quarters, Galls tells investors in a research note. 2018 may well prove to be a reset year for Nutrisystem, the analyst adds. The stock in pre-market trading is down 27%, or $10.80, to $29.10.
02/27/18
RILY
02/27/18
NO CHANGE
Target $52
RILY
Buy
Nutrisystem price target lowered to $52 from $74 at B. Riley FBR
B. Riley FBR analyst Kara Anderson lowered her price target for Nutrisystem to $52 saying marketing missteps in early 2018 drove fiscal year guidance well below consensus. The analyst reduced her estimates but maintains a Buy rating on the shares.
02/27/18
02/27/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Nutrisystem (NTRI) downgraded to Market Perform from Outperform at Barrington by analyst Matthew Gall following last night's Q4 results. The company's flattish guidance for 2018, compared to double-digit growth expectations on sales and earnings, will likely put a ceiling on the stock for the next couple of quarters, Galls said. 2018 may well prove to be a reset year for Nutrisystem, the analyst added. 2. Akcea Therapeutics (AKCA) downgraded to Market Perform from Outperform at Wells Fargo by analyst Jim Birchenough. With a new proposal to reduce volanesorsen dose to biweekly in lighter patients to mitigate risk of severe platelet reduction, the analyst sees increased regulatory risk on questions of adequacy of the lower dose in reducing triglycerides to key threshold levels and in reducing risk of pancreatitis. Shares were also downgraded to Market Perform from Outperform at Cowen and to Hold from Buy at Stifel. Stifel analyst Stephen Willey said that the FDA's upcoming Advisory Committee meeting on May 10 is a potential source of volatility he would prefer to watch from the sidelines. 3. Badger Meter (BMI) downgraded to Sell from Hold at Canaccord Genuity by analyst Chip Moore. With "lackluster" organic growth trends in the company's core utility water metering market and shares trading near all-time peak valuation ranges, the stock has downside risk, Moore said. He believes competitive pressures could be intensifying and that near-term margins are unlikely to move materially higher. 4. Carrizo Oil & Gas (CRZO) downgraded to Sector Weight from Overweight at KeyBanc by analyst Chris Stevens, who said the company in Q4 missed on oil production while capex was high. Further, Q1 production was guided "shockingly low," Stevens said. The Delaware appears a "more challenging place to operate" than expected and the Eagle Ford is "showing signs of fatigue," the analyst contended. Johnson Rice also downgraded shares to Accumulate from Buy. 5. Ingevity (NGVT) downgraded to Hold from Buy at Loop Capital by analyst Chris Kapsch, who cited a more balanced risk/reward at current share levels. The analyst still likes the fundamental story, and raised his price target for the shares to $83 from $80, but cited valuation for the downgrade. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage,
FIT Fitbit
$4.86

-0.68 (-12.27%)

02/27/18
OPCO
02/27/18
NO CHANGE
Target $8
OPCO
Outperform
Fitbit transition starts 'modestly,' says Oppenheimer
Oppenheimer analyst Andrew Uerkwitz says Fitbit reported another "uninteresting" quarter. But with reactivations, cash being essentially flat, and recent digital health acquisitions, the analyst remains "ever the optimist." Uerkwitz reiterates an Outperform rating and $8 price target.
02/27/18
BOFA
02/27/18
NO CHANGE
Target $5
BOFA
Underperform
Fitbit price target lowered to $5,outlook disappoints, says BofA/Merrill
BofA/Merrill analyst Ryan Goodman said Fitbit's Q4 report and outlook fell short of expectations with its new flagship smartwatch, Iconic, experiencing weak sales as it faced competitive challenges. Goodman said the underwhelming reception of Iconic is a "worrisome sign" due to the importance of the launch and raises concerns as to Fitbit's ability to take market share. The analyst lowered his 2018 Fitbit revenue estimate to $1.5B from $1.78B and cut his price target to $5 from $6 given declining revenue, cash burn and product uncertainty, while maintaining and Underperform rating.
02/27/18
STFL
02/27/18
NO CHANGE
Target $5.5
STFL
Hold
Stifel keeps Hold on Fitbit, says expense management reassuring
Stifel analyst Jim Duffy said Fitbit's Q4 results and FY18 outlook were "directionally aligned" with his expectations, though he added that he is reassured by the company's expense management and inventory discipline. Duffy maintains a Hold rating and $5.50 price target on Fitbit, stating that he doesn't yet see a path to profitability and is "challenged to make a compelling upside case" for the stock.
02/27/18
SBSH
02/27/18
NO CHANGE
Target $4.5
SBSH
Sell
Fitbit price target lowered to $4.50 from $5 at Citi
Citi analyst Stanley Kovler lowered his price target for Fitbit to $4.50 citing the company's Q4 miss and guide down. The analyst maintains a Sell rating on the shares.
ABC AmerisourceBergen
$97.64

-2.94 (-2.92%)

02/15/18
BERN
02/15/18
NO CHANGE
BERN
Walgreens/AmerisourceBergen deal a reaction to potential Amazon disruption, says Bernstein
Bernstein analyst Lance Wilkes sees a potential Walgreens (WBA)/AmerisourceBergen (ABC) deal as being a strategic reaction to gross margin pressures and potential disruption from Amazon (AMZN). His initial view is neutral to this deal, as he does not see it as strategically attractive, given his long-term concerns on the distributor role given his expectation of Amazon disruption to retail pharmacy. Wilkes would expect near-term synergies to be more limited, given the existing relationships between the companies and Walgreens's attractive economics already being achieved through the generic consortium.
02/27/18
BOFA
02/27/18
INITIATION
Target $111
BOFA
Buy
AmerisourceBergen reinstated with a Buy at BofA/Merrill
BofA/Merrill analyst Michael Cherny reinstated coverage on AmerisourceBergen with a Buy and $111 price target.
02/14/18
JEFF
02/14/18
NO CHANGE
JEFF
Amazon focusing on bolstering medical device distribution, says Jefferies
Yesterday's Wall Street Journal report and a recent scan of job postings still point to Amazon.com's (AMZN) focus on bolstering its medical device/supplies distribution capabilities, specifically targeting hospitals, Jefferies analyst Brian Tanquilut. These postings support a negative thesis for Cardinal Health (CAH), Owens & Minor (OMI) and Premier's (PINC) medical supplies businesses, the analyst adds. Further, he sees the news as an incremental positive for AmerisourceBergen (ABC), McKesson (MCK), CVS Health (CVS) and Walgreens Boots Alliance (WBA) since it further supports the view that Amazon isn't looking to enter the prescription business near-term.
02/27/18
COWN
02/27/18
NO CHANGE
Target $108
COWN
Outperform
AmerisourceBergen selloff on CNBC report brings buying opportunity, says Cowen
The selloff in shares of AmerisourceBergen (ABC) after CNBC reported that discussions with Walgreens Boots Alliance (WBA) regarding a merger have ended with no agreement presents a buying opportunity, Cowen analyst Charles Rhyee tells investors in an intraday research note. AmerisourceBergen is down 5%, or $4.98, to $95.60 in afternoon trading. The company's underlying fundamentals "remain on solid footing" and current valuation levels "still look compelling," Rhyee contends. The analyst keeps an Outperform rating on AmerisourceBergen with a $108 price target.
WBA Walgreens Boots Alliance
$69.14

-1.46 (-2.07%)

02/27/18
BOFA
02/27/18
INITIATION
Target $76
BOFA
Neutral
Walgreens Boots Alliance reinstated with a Neutral at BofA/Merrill
BofA/Merrill analyst Michael Cherny reinstated coverage on Walgreens Boots Alliance with a Neutral and $76 price target.
CMCSK Comcast
$58.00

(0.00%)

01/11/18
PIPR
01/11/18
NO CHANGE
Target $25
PIPR
Overweight
Piper confident TiVo can renew with Comcast as legal fight continues
After TiVo (TIVO) reported that it has filed new lawsuits against Comcast (CMCSA) and said it plans to further a prior ITC court win, Piper Jaffray analyst Michael Olson said he believes these additional suits are intended to show that TiVo is not backing down in its legal battle. The analyst, who said he has a high degree of confidence in the company successfully renewing with Comcast, keeps his Overweight rating and $25 price target on TiVo shares.
01/09/18
MSCO
01/09/18
NO CHANGE
Target $50
MSCO
Overweight
Comcast price target raised to $50 on tax reform benefits at Morgan Stanley
Morgan Stanley analyst Benjamin Swinburne raised his FY18 and FY19 EPS estimates for Comcast, each by 20%, calling it the "big tax winner" as he views the company specifically, and cable in general, as among the largest tax reform beneficiaries in the market. The analyst, who also cites expectations for strong organic growth in its Cable segment and the benefits of this being both an Olympics and Super Bowl year at NBC in supporting his view that Comcast can outperform in 2018, raised his price target on the stock to $50 from $44 and keeps an Overweight rating on the name.
SKYAY Sky
$74.58

12.98 (21.07%)

04/26/17
JEFF
04/26/17
UPGRADE
JEFF
Buy
Sky upgraded to Buy from Hold at Jefferies
Price target GBP 1,200p.
08/01/17
FBCO
08/01/17
NO CHANGE
Target $37
FBCO
Outperform
21st Century Fox, Sky deal to take longer to clear, says Credit Suisse
Credit Suisse analyst Omar Sheikh continues to believe the Sky (SKYAY) transaction will eventually receive full regulatory approval, but highlights there is an elevated risk to the deal if it is referred to the CMA, and at best an extended period before it gets cleared. Meanwhile, he believes the 2018 21st Century Fox (FOXA) organic equity story looks compelling, and reiterates an Outperform rating and $37 price target on the shares.
10/12/17
FBCO
10/12/17
NO CHANGE
Target $35
FBCO
Outperform
21st Century Fox price target lowered to $35 from $37 at Credit Suisse
Credit Suisse analyst Omar Sheikh lowered his price target for 21st Century Fox (FOXA) to $35 from $37 ahead of Q1 earnings. The analyst notes that the key near-term headwinds are soft NFL ratings and the risk that the Sky (SKYAY) transaction is blocked by U.K. regulators. The analyst reiterates an Outperform rating on 21st Century Fox shares.
FOX 21st Century Fox
$37.14

-1.26 (-3.28%)

12/13/17
BTIG
12/13/17
NO CHANGE
BTIG
Disney, Fox deal may be a near-term positive for Netflix, BTIG says
Commenting on Disney's (DIS) deal with Fox (FOX; FOXA) and its potential implications, BTIG's Richard Greenfield notes that the knee jerk reaction he hears across the investment world is the former is buying the later to build their "Netflix killer." Greenfield "strongly disagrees" with this viewpoint, saying that if Disney wanted to build a Netflix competitor it should be eliminating its stock buyback and aggressively investing in content that has no legacy media strings attached. Further, the Disney/Fox transaction is likely a near-to-intermediate term positive for Netflix, he argues, adding that both companies will be tied up in a 12 month or more regulatory review process with thousands of executives in limbo pending the closing of the transaction.
12/18/17
UBSW
12/18/17
NO CHANGE
Target $122
UBSW
Buy
Disney deal for Fox fits both strategically and financially, says UBS
UBS analyst John Hodulik said Disney's (DIS) deal for Fox (FOXA) strengthens its asset base amid the evolving media landscape and fits well both strategically and financially. He believes the deal enhances Disney's growth trajectory and will be accretive to 2020 free cash flow while helping it widen its appeal and target audience. Hodulik reiterated his Buy rating and $122 price target on Disney shares.

TODAY'S FREE FLY STORIES

TWTR

Twitter

$44.49

-0.775 (-1.71%)

12:44
07/15/18
07/15
12:44
07/15/18
12:44
Periodicals
Twitter suspends accounts linked to Russians indicted by Mueller, Reuters says »

Twitter has suspended two…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

  • 27

    Jul

SPY

SPDR S&P 500 ETF Trust

$279.57

0.3 (0.11%)

, SPX

S&P 500

$0.00

(0.00%)

12:29
07/15/18
07/15
12:29
07/15/18
12:29
Periodicals
Trump says he will run for reelection, Reuters reports »

President Donald Trump…

SPY

SPDR S&P 500 ETF Trust

$279.57

0.3 (0.11%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EADSY

Airbus

$0.00

(0.00%)

12:22
07/15/18
07/15
12:22
07/15/18
12:22
Periodicals
Airbus in talks for repeat Viva Aerobus jet order, Reuters says »

Airbus is in talks with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$350.81

4.79 (1.38%)

12:19
07/15/18
07/15
12:19
07/15/18
12:19
Periodicals
Boeing concerned about tariff talk, Reuters reports »

Boeing is concerned about…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

SPY

SPDR S&P 500 ETF Trust

$279.57

0.3 (0.11%)

, SPX

S&P 500

$0.00

(0.00%)

12:17
07/15/18
07/15
12:17
07/15/18
12:17
Periodicals
President Trump calls EU a 'foe' on trade, Reuters reports »

President Donald Trump…

SPY

SPDR S&P 500 ETF Trust

$279.57

0.3 (0.11%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LLL

L3 Technologies

$203.32

1.29 (0.64%)

12:14
07/15/18
07/15
12:14
07/15/18
12:14
Hot Stocks
L3 Technologies appoints new SVP, Chief Global Business Development Officer »

L3 Technologies has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$207.33

0.43 (0.21%)

, TWTR

Twitter

$44.49

-0.775 (-1.71%)

13:27
07/14/18
07/14
13:27
07/14/18
13:27
Periodicals
Facebook, Alphabet to testify at U.S. House hearing, Reuters reports »

The U.S. House Judiciary…

FB

Facebook

$207.33

0.43 (0.21%)

TWTR

Twitter

$44.49

-0.775 (-1.71%)

GOOG

Alphabet

$1,188.81

4.94 (0.42%)

GOOGL

Alphabet Class A

$1,204.34

2.43 (0.20%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

  • 23

    Jul

  • 23

    Jul

  • 25

    Jul

  • 27

    Jul

  • 08

    Aug

  • 18

    Sep

  • 28

    Oct

AAPL

Apple

$191.32

0.19 (0.10%)

, T

AT&T

$31.66

-0.56 (-1.74%)

13:06
07/14/18
07/14
13:06
07/14/18
13:06
Periodicals
Apple's next iPhone may be debut of eSIM, Barron's says »

Apple's (AAPL) next…

AAPL

Apple

$191.32

0.19 (0.10%)

T

AT&T

$31.66

-0.56 (-1.74%)

VZ

Verizon

$51.41

0.17 (0.33%)

S

Sprint

$5.66

(0.00%)

TMUS

T-Mobile

$61.68

0.09 (0.15%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

  • 09

    Aug

AEP

American Electric

$70.37

-0.02 (-0.03%)

, NEE

NextEra Energy

$169.60

1.06 (0.63%)

12:57
07/14/18
07/14
12:57
07/14/18
12:57
Periodicals
Utility stocks worth a second look, Barron's says »

Utility stocks like…

AEP

American Electric

$70.37

-0.02 (-0.03%)

NEE

NextEra Energy

$169.60

1.06 (0.63%)

XEL

Xcel Energy

$46.26

-0.09 (-0.19%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 26

    Jul

AVGO

Broadcom

$202.46

-7.45 (-3.55%)

, CA

CA Technologies

$44.07

-0.08 (-0.18%)

12:50
07/14/18
07/14
12:50
07/14/18
12:50
Periodicals
Broadcom testing investors' faith, Barron's says »

For a while, shareholders…

AVGO

Broadcom

$202.46

-7.45 (-3.55%)

CA

CA Technologies

$44.07

-0.08 (-0.18%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VRX

Valeant

$23.40

-0.84 (-3.47%)

, HLF

Herbalife Nutrition

$53.95

-0.14 (-0.26%)

12:16
07/14/18
07/14
12:16
07/14/18
12:16
Periodicals
Ackman might be making a comeback, Barron's says »

Bill Ackman's…

VRX

Valeant

$23.40

-0.84 (-3.47%)

HLF

Herbalife Nutrition

$53.95

-0.14 (-0.26%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Aug

  • 27

    Aug

ARNC

Arconic

$17.39

0.08 (0.46%)

, APO

Apollo Global

$36.13

0.26 (0.72%)

08:41
07/14/18
07/14
08:41
07/14/18
08:41
Periodicals
Apollo, other PE firms express interest in Arconic, WSJ reports »

Arconic (ARNC) has…

ARNC

Arconic

$17.39

0.08 (0.46%)

APO

Apollo Global

$36.13

0.26 (0.72%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Aug

PFE

Pfizer

$37.53

0.01 (0.03%)

, BABA

Alibaba

$190.03

-0.14 (-0.07%)

08:23
07/14/18
07/14
08:23
07/14/18
08:23
Hot Stocks
Week in review: How Trump's policies moved stocks »

Catch up on the top…

PFE

Pfizer

$37.53

0.01 (0.03%)

BABA

Alibaba

$190.03

-0.14 (-0.07%)

BIDU

Baidu

$267.20

-4.31 (-1.59%)

JD

JD.com

$38.27

-0.25 (-0.65%)

IQ

iQIYI

$33.92

-1.12 (-3.20%)

VIPS

Vipshop

$10.23

-0.09 (-0.87%)

NYT

New York Times

$25.60

-0.6 (-2.29%)

PLNT

Planet Fitness

$48.71

1.2 (2.53%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

  • 10

    Sep

  • 10

    Sep

XYL

Xylem

$68.55

0.485 (0.71%)

, AQUA

Evoqua Water

$20.71

(0.00%)

04:55
07/14/18
07/14
04:55
07/14/18
04:55
Conference/Events
RBC Capital to hold a field trip »

Asia Water Sector Field…

XYL

Xylem

$68.55

0.485 (0.71%)

AQUA

Evoqua Water

$20.71

(0.00%)

DHR

Danaher

$99.25

-0.4 (-0.40%)

PNR

Pentair

$43.53

0.67 (1.56%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

  • 25

    Jul

  • 07

    Aug

HJLI

Hancock Jaffe Laboratories

$3.20

-0.025 (-0.78%)

18:20
07/13/18
07/13
18:20
07/13/18
18:20
Hot Stocks
Hancock Jaffe Laboratories names Bob Rankin as CFO, effective July 16 »

Hancock Jaffe…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CKH

Seacor

$53.63

0.69 (1.30%)

, LPG

Dorian LPG

$7.92

0.115 (1.47%)

18:16
07/13/18
07/13
18:16
07/13/18
18:16
Hot Stocks
Seacor favors combination of Dorian LPG and BW LPG Limited »

Seacor (CKH) announced…

CKH

Seacor

$53.63

0.69 (1.30%)

LPG

Dorian LPG

$7.92

0.115 (1.47%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Oct

ZTCOY

ZTE Corp.

$0.00

(0.00%)

17:53
07/13/18
07/13
17:53
07/13/18
17:53
Hot Stocks
Senator Rubio says ZTE 'should be put out of business' »

U.S. Senator Marco Rubio…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Sep

TEVA

Teva

$23.29

-0.45 (-1.90%)

, NVS

Novartis

$78.78

-0.15 (-0.19%)

17:47
07/13/18
07/13
17:47
07/13/18
17:47
Hot Stocks
FDA announces voluntary recall of several medicines containing valsartan »

The U.S. Food and Drug…

TEVA

Teva

$23.29

-0.45 (-1.90%)

NVS

Novartis

$78.78

-0.15 (-0.19%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Sep

  • 16

    Sep

SKY

Skyline

$32.54

-0.13 (-0.40%)

17:26
07/13/18
07/13
17:26
07/13/18
17:26
Syndicate
Breaking Syndicate news story on Skyline »

Skyline files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SKY

Skyline

$32.54

-0.13 (-0.40%)

17:25
07/13/18
07/13
17:25
07/13/18
17:25
Syndicate
Breaking Syndicate news story on Skyline »

Skyline files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MBIO

Mustang Bio

$7.49

0.09 (1.22%)

17:24
07/13/18
07/13
17:24
07/13/18
17:24
Syndicate
Breaking Syndicate news story on Mustang Bio »

Mustang Bio files $75M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLE

Energy Select Sector SPDR

$76.26

0.42 (0.55%)

, XLU

Utilities SPDR

$52.56

0.04 (0.08%)

17:15
07/13/18
07/13
17:15
07/13/18
17:15
General news
Week ending ETF Scorecard: Industrials rebound into lead, Utilities lag »

S&P500 SECTORS:…

XLE

Energy Select Sector SPDR

$76.26

0.42 (0.55%)

XLU

Utilities SPDR

$52.56

0.04 (0.08%)

IYR

DJ US Real Estate Index Fund

$81.37

-0.19 (-0.23%)

XLP

Consumer Staples Sector SPDR

$52.73

0.32 (0.61%)

XLY

Consumer Discretionary Sector SPDR

$112.62

0.27 (0.24%)

XLB

S&P Select Materials SPDR

$58.59

-0.02 (-0.03%)

XLF

Financial Select Sector

$26.96

-0.13 (-0.48%)

XLV

Health Care Select Sector SPDR

$87.44

0.18 (0.21%)

XLK

Technology Select Sector SPDR

$72.56

-0.07 (-0.10%)

XLI

Industrial Select Sector SPDR

$73.77

0.43 (0.59%)

GLD

SPDR Gold Trust

$117.60

-0.515 (-0.44%)

SLV

iShares Silver Trust

$14.88

-0.13 (-0.87%)

USO

United States Oil Fund

$14.47

0.085 (0.59%)

UNG

United States Natural Gas Fund

$22.40

-0.3 (-1.32%)

HYG

iShares iBoxx $ High Yield Corporate Bond

$85.63

0.005 (0.01%)

LQD

iShares iBoxx $ Investment Grade Corporate Bond

$115.76

0.16 (0.14%)

TLT

iShares 20+ Year Treasury Bond Fund

$122.74

0.33 (0.27%)

IEF

iShares 7-10 Year Treasury Bond ETF

$102.60

0.165 (0.16%)

SHY

iShares 1-3 Year Treasury Bond

$83.26

0.025 (0.03%)

IWD

iShares Russell 1000 Value

$123.04

-0.07 (-0.06%)

IWF

iShares Russell 1000 Growth

$149.33

0.33 (0.22%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CVM

CEL-SCI

$1.04

-0.015 (-1.42%)

17:15
07/13/18
07/13
17:15
07/13/18
17:15
Hot Stocks
CEL-SCI receives noncompliance letter from NYSE »

CEL-SCI reported on a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PZZA

Papa John's

$53.47

-0.18 (-0.34%)

17:13
07/13/18
07/13
17:13
07/13/18
17:13
Hot Stocks
Yankees suspend relationship with Papa John's »

The New York Yankees…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

NCNA

NuCana

$24.00

-0.01 (-0.04%)

17:08
07/13/18
07/13
17:08
07/13/18
17:08
Hot Stocks
Breaking Hot Stocks news story on NuCana »

Christopher B. Wood…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.